¹⁸F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study.

ABSTRACT:

Purpose

To determine whether interim 3'-deoxy-3'-[¹⁸F]fluorothymidine (iFLT) PET/CT is a superior predictor of progression-free survival (PFS) compared with interim ¹⁸F-fluorodeoxyglucose (iFDG) PET/CT in patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH).

Methods

Ninety-two prospectively enrolled patients with DLBCL underwent both FLT-PET/CT and FDG-PET/CT 18-24 days after two cycles of R-CHOP/R-EPOCH. Deauville-criteria, PERCIST1.0, standardized uptake value (SUV), total lesion glycolysis (TLG), and metabolic tumor volume were used to interpret iFDG-PET/CT while dicho

SUBMITTER: Minamimoto R 

PROVIDER: S-EPMC8263539 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature